drugset
drugset / Trial / NCT02805218

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

NCT02805218 ↗

Phase 4 Completed 410 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Timeline

Start
2013-09
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 100 ug/kg Subcutaneous

Indications

lymphoma